This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Hosts Annual Meeting Of Shareholders

The board of directors of Pfizer Inc. today declared a 22-cent second-quarter 2012 dividend on the company’s common stock, payable June 5, 2012, to shareholders of record at the close of business on May 11, 2012. The second-quarter 2012 cash dividend will be the 294 th consecutive quarterly dividend paid by Pfizer.

“Through dividends and share repurchases, we returned approximately $15.2 billion to our shareholders in 2011,” said Ian Read, chairman and chief executive officer. “In 2012, we are continuing to take actions to increase shareholder value, including through our dividend increase announced in December 2011, and continued share repurchase activity. In addition, we recently announced an agreement to sell our Nutrition business to Nestlé for $11.85 billion, and we remain on track to announce a strategic decision for our Animal Health business in 2012.”

Preliminary results from the meeting indicate that the company’s 14 continuing directors were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer’s independent registered public accounting firm for the 2012 fiscal year. In addition, shareholders voted in support of a board-sponsored proposal to approve, on an advisory basis, the compensation of the company’s named executive officers.

In other voting, four shareholder proposals were not approved by the shareholders.

The final results are subject to verification by the independent election inspectors. The final results will be reported in a Form 8-K to be filed by Pfizer with the Securities and Exchange Commission in the next few days.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with healthcare professionals, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at  www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of April 26, 2012. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about the Company’s plans with respect to dividends and share repurchases, about an agreement to sell the Nutrition business to Nestle and about the Company’s plan to announce a strategic decision regarding its Animal Health business that involves substantial risks and uncertainties. A description of these risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Forms 10-Q and 8-K.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,159.22 +117.68 0.65%
S&P 500 2,121.37 +17.17 0.82%
NASDAQ 5,093.7140 +60.9630 1.21%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs